Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Monoclonal Antibodies Against Poliovirus

Posted Aug 11 2011 8:00pm

Description of Invention:
Early work by Hammond at al. showed gamma globulin to be effective for the prevention of poliomyelitis. Therefore, passive immunotherapy could be another way to treat chronic excretors. Even though prior attempts to use intravenous immunoglobulin (IVIG) and breast milk were unsuccessful, there is reason to think that higher doses of antipoliovirus antibodies could result in complete clearance of poliovirus from chronically infected individuals. Six poliovirus-neutralizing MAbs were recovered from a combinatorial Fab phage display library constructed from bone marrow-derived lymphocytes of immunized chimpanzees. The six MAbs neutralized vaccine strains and virulent strains of poliovirus. Five MAbs were serotype specific, while one MAb cross-neutralized serotypes 1 and 2. Both serotype 2-specific antibodies recognized antigenic site 1. No escape mutants to serotype 3-specific MAbs could be generated. The administration of a serotype 1-specific MAb to transgenic mice susceptible to poliovirus at a dose of 5 µg/mouse completely protected them from paralysis after challenge with a lethal dose of wild-type poliovirus. Moreover, MAb injection 6 or 12 h after virus infection provided significant protection. This application claims the antibodies described above and methods for their use.

Applications:
  • Prophylaxis/therapeutic for poliovirus.
  • Post-exposure emergency prophylaxis of poliovirus.


Advantages:
  • No humanization required.
  • Highly potent neutralizing antibodies.
  • Biological materials available.


Development Status:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Zhaochun Chen (NIAID)
Robert H Purcell (NIAID)
Konstantin M Chumakov (FDA)


Patent Status:
HHS, Reference No. E-076-2011/0
US, Application No. 61/443,915 filed 17 Feb 2011


Relevant Publication:
  1. Chen Z, et al. [ PMID 21345966 ]



For Licensing Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220


Ref No: 2306

Updated: 08/2011

Post a comment
Write a comment:

Related Searches